Compare GE & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GE | MRK |
|---|---|---|
| Founded | 1892 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.8B | 260.2B |
| IPO Year | N/A | N/A |
| Metric | GE | MRK |
|---|---|---|
| Price | $321.96 | $110.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 15 |
| Target Price | ★ $319.30 | $115.27 |
| AVG Volume (30 Days) | 4.7M | ★ 14.3M |
| Earning Date | 01-22-2026 | 02-03-2026 |
| Dividend Yield | 0.46% | ★ 3.06% |
| EPS Growth | 31.94 | ★ 58.08 |
| EPS | 7.50 | ★ 7.56 |
| Revenue | $43,950,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $10.92 | $1.98 |
| Revenue Next Year | $11.85 | $4.94 |
| P/E Ratio | $41.92 | ★ $14.69 |
| Revenue Growth | ★ 17.68 | 1.68 |
| 52 Week Low | $159.36 | $73.31 |
| 52 Week High | $332.79 | $112.90 |
| Indicator | GE | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 72.95 |
| Support Level | $310.27 | $104.43 |
| Resistance Level | $332.79 | $112.90 |
| Average True Range (ATR) | 6.95 | 2.19 |
| MACD | 0.90 | 0.30 |
| Stochastic Oscillator | 61.34 | 81.74 |
GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000 until GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).